HALEOS LABS LIMITED (NSE: HALEOSLABS, BSE: 540679) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹423 Cr, it ranks #2,107 by market cap among the 6,197 Indian listed companies on FinBizNet, and #29 of 63 in Pharmaceuticals. At ₹1,588.90 (as of 16 Nov 2026), the share price is 10.4% below its 52-week high of ₹1,774.00 and 45.6% above its 52-week low of ₹1,091.10. The share price is up 38.2% over one year and up 7.8% over three months.
| Current Price | ₹1,588.90 |
|---|---|
| Market Cap | ₹423 Cr |
| NSE Symbol | HALEOSLABS |
| BSE Code | 540679 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 27.9 |
| Return on Equity | 8.06% |
| Return on Assets | 4.45% |
| 52-Week Range | ₹1,091.10 – ₹1,774.00 |
| 1-Year Price Change | +38.2% |
| 3-Month Price Change | +7.8% |
| Beta (1Y) | 0.34 |
| Dividend Yield | 0.09% |
| Headquarters | Hyderabad, Telangana |
| Website | haleoslabs.com |
| Revenue | ₹91 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 1.9% |
| EPS (Basic) | ₹10.77 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
HALEOS LABS LIMITED reported revenue of ₹91 Cr in Q2 FY27, up 12.3% from ₹81 Cr in Q2 FY26 and up 25.3% from ₹73 Cr in Q1 FY27. It posted a net profit of ₹2 Cr for the quarter, against a net profit of ₹6 Cr in Q2 FY26 (down 72.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹73 Cr (Q1 FY27) to ₹95 Cr (Q3 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹91 Cr | ₹2 Cr | 1.9% |
| Q1 FY27 | ₹73 Cr | ₹2 Cr | 2.5% |
| Q4 FY26 | ₹75 Cr | ₹0 Cr | 0.5% |
| Q3 FY26 | ₹95 Cr | ₹7 Cr | 7.0% |
| Q2 FY26 | ₹81 Cr | ₹6 Cr | 7.9% |
| Q1 FY26 | ₹83 Cr | ₹4 Cr | 5.3% |
| Q4 FY25 | ₹89 Cr | ₹3 Cr | 3.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 72.11% of HALEOS LABS LIMITED's shares as of Sept 2026, against 71.41% in Sept 2025 (+0.70 percentage points). Delivery averaged 78.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
1. Pharmaceutical-This segment researches, develops, manufactures, buys, imports, sells, and exports active pharmaceutical ingredients and its intermediates. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing of Active Pharmaceutical Ingredients and Their Intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| HALEOS LABS LIMITED | ₹423 Cr | 27.9 | 8.06% | ₹91 Cr | +38.2% |
Listed by market capitalisation. Ratios are shown for context only.
HALEOS LABS LIMITED is trading at ₹1,588.90, with a market capitalisation of ₹423 Cr.
HALEOS LABS LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
HALEOS LABS LIMITED has a P/E of 27.9 and a return on equity of 8.06%.
HALEOS LABS LIMITED is listed on the NSE under the symbol HALEOSLABS and on the BSE under the scrip code 540679.
HALEOS LABS LIMITED's share price is up 38.2% over one year and up 7.8% over three months. Its 52-week range is ₹1,091.10 to ₹1,774.00.
In Q2 FY27, HALEOS LABS LIMITED reported revenue of ₹91 Cr and net profit of ₹2 Cr, with basic EPS of ₹10.77 (consolidated, parsed from the company's exchange filing).
HALEOS LABS LIMITED reported revenue of ₹91 Cr in Q2 FY27, up 12.3% from ₹81 Cr in Q2 FY26 and up 25.3% from ₹73 Cr in Q1 FY27.
Promoters held 72.11% of HALEOS LABS LIMITED's shares as of Sept 2026, against 71.41% in Sept 2025 (+0.70 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.